• Pharmaceutical and health care services company Trxade Group Inc. is enjoying growing attention as it continues to roll out remote-access medical solutions that are suited to the ongoing COVID-19 pandemic and the need to prevent virus transmission
• The company will announce its second quarter financial report July 27 following the close of markets that day
• Telehealth claims to private insurers have grown by 4,347 percent year-over-year during the past few months in which the pandemic has swept the planet
• Trxade Group’s introduction of the Bonum Health Hub and online pharmaceutical ordering and delivery services has driven the company’s customer responsiveness during the pandemic
• The company’s core focus has been to sustain independent pharmaceutical and health care providers by helping them gain access to transparency in drug pricing and other aspects of business so they can be competitive with larger chains

Pharmaceutical services provider Trxade Group (NASDAQ: MEDS) has seen its star rising during recent months while working to raise awareness of its medical consultation and prescription drug solutions. As the spread of the novel coronavirus unexpectedly reached pandemic proportions and battered world economies with its infectious spread and the resulting infection-fighting policies, Trxade Group has advanced measures that help patients and providers continue to access resources through a virtual environment safe from contagion.

On July 27, Trxade Group’s management will host a conference call following the close of trading at 5 p.m. EDT to discuss the company’s 2020 second quarter financial results, which will conclude with a Q&A opportunity for participants. Details published by the company provide phone-in numbers for U.S. and international participants as well as the conference ID and the address for the webcast (http://nnw.fm/dq8Bl).

A playback of the conference call will be available through Aug. 27, as will the webcast. The webcast will also be accessible under the company website’s investor relations heading.

Trxade Group uplisted to the Nasdaq exchange earlier this year (http://nnw.fm/MSaiI) and last month it gained inclusion on this year’s Russell’s Microcap Index (http://nnw.fm/0tU7a), measures that are helping to raise the company’s profile within the investment community. Investment services firm Taglich Brothers, Inc. has begun providing coverage to Trxade through its research division as well to create and distribute research reports on the company and its market (http://nnw.fm/mkaNx).

Even before the emergence of the pandemic, Trxade Group was introducing and bolstering services that help small, independent pharmacies to shop competitively for medications, patients to have those medications delivered promptly and safely without the need for traveling to a pharmacy, as well as medical providers to be accessible through smart-tech secured telemedicine applications.

Strategic acquisition of Internet drug outlet company Community Specialty Pharmacy, LLC, (http://nnw.fm/Nzp1l) and Bonum Health (http://nnw.fm/vwdIg) has allowed the company to lay the groundwork for an increased demand on telehealth services.

During the COVID-19 crisis, telehealth services have seen astronomical expansion. Telehealth claims to private insurers have grown 4,347 percent year-over-year (http://nnw.fm/KdQP2), CVS Health saw 600 percent growth in telehealth and virtual visits through its MinuteClinics in the first quarter of 2020 (http://nnw.fm/iabaP), Blue Cross and Blue Shield of Tennessee saw 50 times more telehealth visits in May compared to their normal amount (http://nnw.fm/HoW3M) and Blue Cross of Idaho processed more than 90,500 telehealth claims between March and June, with telehealth now representing more than one-quarter of all claims (http://nnw.fm/z9xpo).

If the telemedicine services remain popular with patients and insurance providers continue to be responsive to reimbursing telehealth claims, market analysts at McKinsey & Company forecast a $250 billion market (http://nnw.fm/zYUhR) while Frost & Sullivan projects a seven-fold increase by 2025 (http://nnw.fm/eEivE).

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

With the emergence of new technology, the Veterans Affairs Department in on the verge of overhauling its electronic health record system. As innovations are coming into existence, there is also a need to digitize the health records. Besides, the department wants to examine if the robotic automation of health records can work. The first deployment of the electronic health record was planned to take place at Mann-Grandstaff Medical Center in Spokane, Washington, in March. Congress later pushed the launch to July, but it did not materialize. However, the launch did not take place in July as the Veteran Affairs Department was also engaged in the fighting the COVID-19 pandemic.

Digitalization of Electronic Health Records

As the system is almost reaching its full capacity, VA staff and health care providers will have to ensure all the records are digitalized, and they will also be linked with the correct patients and clinicians. However, this process of deploying and integrating electronic health systems is always complicated if the data is not machine-readable. To manage this, The VA is adopting robotic process automation as a potential solution.

Concrete automation processes are also being investigated by the Department of Veteran Affairs to help in streamlining of the external clinical documents into its electronic health record system. The VA also plans to use the automated system to select some of the digitization backlogs since 2018. These records, if not digitized and stored in hard copies, may reach five-mile high when stored.

Besides, the VA is also planning to integrate the use of a robotic process automation system, the agency-built VistA EHR system and new Cerner Millennium to improve its records. For the successful automation of electronic health records, it needs to have the following three core values.

• Should have the ability to automate the document scanning process, including ingesting and indexing of documents in the EHR platform and connecting it to the right patient and clinician.
• Provide metrics to solve problems and help with the planning of future RPA.
• Identify documents that cannot be automatically ingested and forward them for human processing.

The success of this process will be determined by the number of documents that will be processed within a given period. Furthermore, the accuracy of the program will also be determined by the correct linking of patient documents with the caregiver. The successful digitization of health records will also be measured by the ability of the algorithm to improve and learn, especially when coversheets with relevant information are not mixed with documents.

Experts believe that this step taken by the VA will be welcomed by biomedical companies like Predictive Oncology (NASDAQ: POAI) since medical data stored in the latest digital formats can help a great deal in research and tracking trends among patients.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• POAI completes acquisition designed to accelerate commercialization of proprietary AI-driven drug discovery, development
• Strategic move allows for one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates
• Company to offer new capability to pharmaceutical company customers in revenue-generating projects later this year

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, has completed its acquisition of Quantitative Medicine (“QM”) (http://ibn.fm/vqmwL). POAI signed a letter of intent to acquire QM, a biomedical analytics and computational biology company, in January (http://ibn.fm/4iRTV). The strategic move should accelerate the commercialization of Predictive Oncology’s proprietary AI-driven drug discovery and development.

“This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing,” said POAI CEO Dr. Carl Schwartz. “Integrating QM’s proven machine-learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers.

“We will be able to more quickly understand how specific types of tumors react to cancer drug therapies,” Schwartz continued. “This will allow our customers to accelerate the development and commercialization of personalized patient treatments that dramatically improve patient outcomes. We intend to offer this new capability to our pharmaceutical company customers in revenue generating projects this year.”

Founded by Dr. Robert Murphy and Dr. Joshua Kangas, both of Carnegie Mellon University, QM has developed a novel, computational drug-discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs by predicting the main effects of drugs on target molecules that mediate disease.

“CoRE is a predictive model-building platform for drug screening and optimization campaigns that uses hybrid machine learning approaches to build predictive models rapidly and drive wet-lab experimentation,” said Schwartz. “Unlike the approach of many AI companies working purely ‘in silico,’ our approach will unite the CoRE approach with our PDx tumor-profiling platform and tumor-data database, allowing for a one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates in a cost-effective manner. Therapeutic candidates developed by this iterative AI and experiment cycle can be fast-tracked, since there will already be demonstrated activity in preclinical laboratory tests rather than just a computer model.”

The acquisition was completed in an all-stock transaction valued at approximately $1.8 million, Under the terms of the purchase agreement, POAI issued 954,719 shares of common stock at a valuation of $1.833 per share.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

You may have heard about machine learning and data science in different aspects of life, such as in how your insurance premiums are determined. But, did you know that machine learning and data science are playing an increasing role in public health? Read on and learn about this exciting development.

What is Big Data?

It refers to the massive amount of information, such as data from administrative health claims and biobanks, which is available to researchers in a de-identified fashion. Furthermore, it is termed as significant due to the undiluted number of people represented in hundreds of millions and also the massive amount of information of the people involved.

It contains vital information, such as their genomes and postal codes. The primary function of these datasets is not always research but for other purposes such as billing. However, one should always ask this natural question, “Are these sets of information useful for public health surveillance and health related discoveries?”

Promises of Machine Learning and Data Science in Health

Machine learning and data sciences are one of the surest ways of summering big data. Besides, the process will predict and validate the data patterns, thus making sense to both doctors, policymakers and patients. Machine learning will also analyze a complicated relationship between variables and find links between environmental or clinical factors and risk for disease.

Secondly, machine learning will also lead to improvement and accuracy in disease diagnosis from medical image analysis. For example, it leads to an improvement in automatic screening for diabetic retinopathy. Google and its collaborators have also proven that machine/deep learning can easily automate image analysis at the highest accuracy levels. Furthermore, it has also been compared to the very best physician examiners in its working processes.

Machine learning has also led to the integration of data types for better understanding of complex associations between environment, genetics and disease. For instance, Harvard University has used large datasets in trying to untangle the relationship between environment and genetics in all diseases. The study has been aided by machine learning due to the large amount of data recorded in health insurance.

Besides using biobanks, machine learning has also been used by scientists in discerning new genetic variants such as environment-wide association studies and genome-wide association studies. The studies have been conducted to help in identifying novel associations with a high-risk diseases that might be missed while studying one at a time.

Challenges Associated with Machine Learning

Machine learning may lead to limited generalization, confusion and even complex correlations between variables. Besides, new modelling using machine learning may not be easily explained by policymakers and physicians. Analysts may be faced with various challenges of the variables to model and which one to be ignored. These variables are always arbitrary and may lead to different interpretations and findings.

You can bet that companies like Genprex Inc. (NASDAQ: GNPX) are using machine learning and data science in their operations in order to bring better products to market.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• SRAX Inc.’s BIGtoken platform provides big data insights, analytics derived from its over 16.7 million users
• Big data is increasingly being used by companies, advertisers to adjust their business models, products to cater to customers’ rapidly changing wants and needs
• SRAX has carried out targeted marketing campaigns for variety of large clients which have resulted in positive return on advertising spend
• Recent study by MarketsandMarkets has estimated that Big Data industry will rise to $229.4 billion by 2025, implying growth of 65% over next 5 years

SRAX (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, has long been focused on helping consumers gain control over and monetize their digital data footprints. Through its revolutionary BIGtoken platform, which boasted 16.7 million users as of the end of the first quarter of 2020, SRAX enables its members to provide their advertisers with access to verified consumer data which can in turn help companies better reach and serve their audiences. Now, with a recently released study showing that the ‘Big Data’ market is set to grow from $138.9 billion in 2020 to $229.4 billion in 2025, implying a compounded annualized growth rate of 10.6% (http://nnw.fm/rAKIN), SRAX’s commercial prospects look more promising than ever before.

Big data and its ability to depict online consumer behavior have long been used by companies seeking deeper insights into their customers. Netflix, the world’s largest video-on-demand streaming platform has been one of the early and most avid users of big data analytics. As early as 2009, Netflix famously launched a contest offering a prize of $1 million to the group which could come up with the best algorithm for predicting how customers would like a movie based on previous ratings. Today, the company’s film and TV show recommendation system is said to influence about 80% of the content which is streamed on the company’s platform (http://nnw.fm/7Ddph). In this scenario, the use of big data analytics and the insights derived from Netflix’s hundreds of millions of users has allowed the company to tailor their content to match customer expectations, license or produce new movies and TV shows based on the expected customer response, and ensure that their marketing campaigns are resulting in an adequate return on advertising spend (“ROAS”).

SRAX’s BIGtoken platform has sought to capitalize on the growing demand for big data analytics through its broad user base as well as its extensive range of functionalities. Towards the end of 2019, the platform introduced the BIGtoken Lightning Insights functionality – a revolutionary tool which allows SRAX’s customers to instantly activate research and surveys about virtually any topic and pose it to BIGtoken’s extensive user base. Companies can choose to address their queries to BIGtoken’s extremely wide and diverse user base or opt to target extremely niche demographic and socio-economic sectors through the product’s over 25,000 points of segmentation and receive actionable audience insights within a matter of mere hours (http://nnw.fm/BNGxp).

The platform’s unique capabilities were recently highlighted during a campaign which the Company carried out for the Kraft Heinz Co. Through the use of SRAX’s BIGtoken tool, Kraft was able to launch a targeted marketing campaign which resulted in a 6.6% return on ad spend (http://nnw.fm/lWT6q). SRAX’s management highlighted the potential of their proprietary marketing solution by contrasting the Kraft campaign to those recently carried out by Walmart and Evite, which delivered flat and negative returns, respectively. Moreover, the company also revealed that the positive returns from the marketing campaign had prompted the client to subsequently follow through with a “really big purchase”.

With the use of big data increasingly becoming a priority for any advertiser, SRAX’s BIGtoken platform has devised a method by which it can provide its customers with near instantaneous and actionable intel on-demand, thereby allowing companies to forgo the oftentimes significant investment needed to create an in-house analytics team and rather focus their attention solely on transforming the data gleaned through BIGtoken into productive marketing campaigns.  With the big data industry set to nearly double in size over the next 5 years, SRAX and its proprietary platform seem well-positioned to benefit from the swelling tide of growth.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Personal planning and health preparedness are an essential component for everyone. However, it is more critical for individuals with bleeding problems. Some bleeding disorders, such as von Willebrand disease and hemophilia, are as a result of one lacking a specific clotting protein factor in the blood.

Due to that, people with bleeding disorders are always experiencing excessive bleeding after trauma or injury. Sometimes, they may bleed for no apparent reason at all. In emergency scenarios, their health still depends on easy access to treatment products and prescriptions, proper care and personal needs.

Infusions are always used as a way to help them manage and treat bleeding disorders. The injection helps in clotting of blood, thus stopping the bleeding. Patients with bleeding disorders are always supplied with infusion tools such as needles, tourniquets and syringes. Some of the personal preparedness tips that people with bleeding disorders need to implement for better health include:

Preparing Your Health

Bleeding may occur any time at work, home or during a disaster. It is therefore essential for people with bleeding disorders to have a “go bag.” The go-bag should contain the supplies and medicine they need in treating and managing a bleed when it occurs. People with bleeding disorders should always have the following items in their go-bags:

• Relevant paperwork such as health insurance records, updated medical information and travelling letter describing your bleeding disorder and drugs you take.
• A list of hemophilia treatment centers or hospitals and their contacts along with your designated preferences.
• Diluent, such as normal saline or sterile water, to mix with factor powder.

Helping Others to Help

It is of the essence to identify a caregiver that may help you in times of emergencies. A caregiver is very essential, especially when you are unable to treat yourself. It is also vital to share your diagnosis when you have a bleeding disorder. Moreover, it would be best if you also showed your friend, relatives and workmates the directions on how to respond to your bleeding to save you in emergency cases. Some of the ideas you can share with them may include:

• Teach them about giving the factor by mixing the clotting factor into a syringe and injecting it in the vein.
• Keep a manual book with relevant medical information, such as up-to-date infusion and treatment.
• Post significant phone numbers in various places in the car, around the house and at work.

Talk to Others About Your Diagnosis

It is essential for individuals with bleeding disorders to be actively involved in managing themselves. Parents with children having these disorders also need to train them and also other people on the health and safety of their children. The more people are informed about your health, the better they will care for you. You can use some of these ways to educate people about your bleeding disorders:

• Complete and carry an emergency care letter that shows your diagnosis, treatment guidelines and any other medications.
• Create an in Case of Emergency contact on your phone.
• Put on medical alert ID bracelet engraved with relevant information for healthcare providers and emergency responders.

By following the highlighted measures, people living with health disorders will have a better way of managing their conditions, hence minimum injuries and bleeding. Analysts say it is the plight of patients, such as those with bleeding disorders, which keep biomedical companies like DarioHealth Corp. (NASDAQ: DRIO) working day and night to come up with helpful remedies so that patients can have a better quality of life.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

The most common cause of hereditary colorectal (colon) cancer is Lynch Syndrome (“LS”). People with Lynch Syndrome have a 70% higher risk of developing colorectal cancer in their lifetime than the general population, and colorectal cancer is the leading cause of death among cancer cases in the U.S. Additionally, people with LS often develop colorectal cancer at much younger ages compared to the healthy population. However, there are no specific drugs that cure cancer, but following the set guidelines by the National Institute for Health and Care (“NICE”) in the UK, there may be some significant news. The information discussed below may offer a sigh of relief to the people suffering from colorectal cancer (“CRC”).

Clinical Trials by NICE

Recent clinical trials indicated that taking Aspirin for more than two years reduces the risk of colorectal cancer among people with Lynch Syndrome. In a clinical trial, only 4% of those who were taking daily Aspirin developed CRC as compared to the 7% under placebo group in a sample of 861 people with LS. However, adverse events did not vary significantly between the two groups. Furthermore, further studies are needed to establish the optimum dose and duration of daily Aspirin intake. It will also lead to more understanding of potential long-term effects.

Daily Benefits of Aspirin Might Outshine Harms Among People with Lynch Syndrome

The regular use of Aspirin among people with colorectal cancer and cardiovascular diseases has been a subject of discussion for decades. When Aspirin is used within the broader population, both the benefits and harms must be weighed in comparison. Some of the injuries, such as haemorrhagic stroke and gastrointestinal bleeding, must also be put into consideration. The available evidence is against the use of daily Aspirin, especially for people with average risk. However, for people with Lynch Syndrome, the benefits of using daily Aspirin supersedes the potential harms.

A Potential New Tier-1 Application

If the anticipated draft guidance becomes formalized, it will be the new CDC Tier-1 genomic guideline. Furthermore, it is expected to maintain most of the recommendations by NICE. The proposal has been defined as having a significant and positive impact on public health.

What Next for People with Lynch Syndrome?

For people with Lynch Syndrome, the NICE draft guidance provides an optimistic outlook towards their health. As the final NICE guidelines are on the verge of completion, patients with Lynch Syndrome can talk to health care workers about the ongoing clinical trials. People with Lynch Syndrome should encourage their relatives to go for earlier screenings and interventions because they have higher risks of contracting the disease. The earlier the interventions, the better as prevention is better than cure.

This news is likely to give Lynch Syndrome sufferers lots of hope, and it is such suffering people that keep companies like Predictive Oncology (NASDAQ: POAI) working hard to come up with breakthroughs that change lives.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

The coronavirus crisis has dealt the economy a blow it will take years to recover from. Industries that were especially hit by shut down orders like airlines, restaurants, and tourism are looking at a long, tough road before they can get back to pre-pandemic levels. With all but the most essential businesses shut down and commerce brought to an almost complete standstill, states have lost millions in tax revenues over the past few months. However, proponents for marijuana legalization have argued that marijuana sales could help stimulate the economy as it recovers.

In the weeks before the shutdowns began, cannabis dispensaries saw a spike in sales, and the industry has consistently reported increasing sales, in some cases even breaking monthly records, during the course of the pandemic. The governor of New Jersey believes the state would get a major economic boost from legalizing marijuana. On top of that, he adds it will promote racial justice, especially as countrywide protests against the aggressive policing of black and Hispanic communities continues.

New Jersey Governor Phil Murphy was recently interviewed on the Jim Kerr Anytime radio show, and the state’s ailing economy was discussed. He recognized that the state will have to be innovative to generate more revenue as the coronavirus crisis rages on, and he concurred with a co-host’s assessment that cannabis could be part of the solution. “As you probably know, I’ve been on that from day one. The legislature hasn’t been able to get there yet, but absolutely,” he said.

“That’s, to me, an incredibly smart thing to do. We’re not inventing marijuana, it exists. It’s got a huge social justice piece for me. The overwhelming percentage of persons nailed in our criminal justice system are persons of color. It’s a no brainer in that respect. It’s a job creator, it’s a tax revenue raiser, and it checks a lot of boxes. I hope we’ll get there sooner than later.”

New Jersey allows medical marijuana, and the state recently announced that cannabis dispensaries would now be able to deliver products to their customers. Although the legislature has so far been unable to pass a recreational marijuana legalization bill, they approved legislation to put a referendum on the issue in the November ballot. Additionally, the state Assembly passed a cannabis decriminalization bill last month that would make possession of up to two ounces of cannabis a civil penalty without the threat of jail time.

The sentiments expressed by Gov. Phil Murphy echo what the entire industry, including Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF), has always said about the economic benefits of having a regulated cannabis industry.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Although several states have legalized either medical or recreational marijuana, it remains illegal at the federal level. This duality in legislation means that sometimes, individuals who work with or consume state-legal cannabis face federal repercussions. However, a series of reports for spending bills released by a key House committee contain a wide range of marijuana-related provisions seeking to change this.

The directives from the House Appropriations Committee were attached to spending bills containing legislative reform provisions including previously tabled proposals that would protect state marijuana laws from federal interference as well as protect banks who work with cannabis businesses from federal retaliation. The reports direct federal agencies to reconsider firing federal workers for consuming state-legal marijuana, to promote research into cannabis and fund CBD regulations.

“The Committee encourages OPM to review its policies and guidelines regarding hiring and firing of individuals who use marijuana in states where that individual’s private use of marijuana is not prohibited under the law of the State. These policies should reflect changes to the law on marijuana usage and clearly state the impact of marijuana usage on federal employment,” states a Financial Services and General Government spending bill report.

Another report attached to the Labor, Health and Human Services, Education and Related Agencies funding bill contained a number of marijuana research provisions too. One provision called on the National Institutes of Health (“NIH”) to develop a “multipronged strategy wherein basic and clinical scientists and public health specialists work together to address the opportunities and challenges of cannabis in a comprehensive manner.”

“NIH currently supports a diverse portfolio of research on cannabinoids and the endocannabinoid system, yet this research support typically relies on narrowly tailored program announcements and grants rather than a multipronged strategy wherein basic and clinical scientists and public health specialists work together to address the opportunities and challenges of cannabis in a comprehensive manner. The Committee encourages NIDA to continue supporting a full range of research on the health effects of marijuana and its components, including research to understand how marijuana policies affect public health, to help inform marijuana policy-making in States.”

Members of the committee also noted that there is significant public interest in cannabis research. They made a recommendation to provide protections for universities that would be licensed to carry out these studies.

“Through scientific research, institutions of higher education advance our understanding and knowledge of various aspects of our world. Moreover, when in the public interest, such institutions should be able to conduct such research without fear of reprisal or loss of federal funding.”

Industry watchers believe sector players like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) are hopeful that soon enough, the pressure mounting from House Committees will eventually bear fruit at the federal level and marijuana policies will be reformed to be more progressive.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

It is crystal clear that clinical trials are the surest way to bring new drugs into the market. While most clinical trials are costly, nine out of ten drugs in clinical development are never approved. Most of these treatments fail in clinical trials due to a lack of the desired effect, and some of these failures are attributed to poor target selection during the drug discovery process. Matching the right treatment to the right patient based on molecular biomarkers can bring more promising results in clinical trials.

Precision Medicine Requires Reliable Biomarkers

Precision medicine aims to treat patients as individuals. It also targets treating patients in stratified groups with distinct molecular profiles. Early identification and verification of biomarkers in drug development stages will ensure that the new therapies are tested on the intended patients. Besides, it will save drug development costs and reduce the attrition rate in clinical trials.

Trials that are using biomarkers in selecting patients have a higher probability of proceeding to the next levels. For instance, 10.7% of trials of cancer drugs that used biomarkers in stratifying patients got market approval. Using biomarkers in early trials can give a functional basement on how later trials can be worked to boost their chances of succeeding. Besides, despite rapid growth in precision medicine, only a few percentages of trials are stratifying patients using biomarkers.

Searching for a Perfect Biomarker

Most biological processes relate to proteins, and most drugs do target proteins and not a nucleic acid. Identifying the levels of clinically relevant proteins in samples of patients will give you more insights into the patient’s disease. It will help you in selecting the best treatment and monitor how efficiently it is working.

In the past, insufficient depth and poor reproducibility made proteomics on body fluid less sufficient. But due to new technology, clinical proteomics is becoming an area of interest.

Identification of Reliable Biomarkers from Biological Fluids is Now Possible

Innovative approaches in large scale measuring of proteins is one of the key technological advancements in proteomics. The data-independent acquisition (DIA), as it is known, gives unbiased and comprehensive results. The method is also offering quantitative proteomic profiling, which reveals reproducible and robust biomarkers even in biological fluids.

Need to Go Deep into the Plasma Proteome

Blood plasma is more natural to collect and contains a variety of proteins that indicate what’s taking place in the body of a patient. It is, therefore, a preferred fluid for biomarker discovery. Besides, it also has proteins that originate from the tissues that are nurtured by blood flow, making it a window to the body. As a result, its composition can also change regularly due to biological processes. Large scale plasma proteomics and biomarkers are now achievable according to recent studies by Nestle and Biognosys after a recent study. It was found that the levels of 271 proteins that carry fat around changed significantly after weight loss hence presenting a large number of potential biomarkers candidates. It was concluded that weight loss reduced inflammation and improved the metabolism of patients.

You can bet that biomedical companies like Genprex Inc. (NASDAQ: GNPX) are looking keenly at including the use of biomarkers during their R&D.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• House Select Committee unveils climate plan involving nuclear energy as essential in clean electric-energy production
• Global uranium prices have risen 34% since March 1 amid significant production cuts
• Energy Fuels uniquely positioned as leading U.S. uranium producer and recycler, set to capitalize on growing nuclear energy role

As the largest uranium miner in the United States, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is poised to capitalize on the government’s recent push for nuclear energy. On June 30, the U.S. House Select Committee on the Climate Crisis released an action plan titled “Solving the Climate Crisis: The Congressional Action Plan for a Clean Energy Economy and a Healthy, Resilient, and Just America” that calls for net-zero greenhouse gas emissions by 2050, and net-negative emissions after that (http://nnw.fm/1ukD3). In addition, the committee’s detailed plan notes that Congress should establish a national clean-energy standard that encourages zero-emission carbon technologies — such as nuclear — to achieve net-zero emissions in the electricity sector by 2040

Recognizing that a substantial reduction in greenhouse gas emissions of the electrical energy sector is needed to minimize the effects of climate change, the report highlights nuclear power as the largest source of carbon-free energy in the country. As such, nuclear energy has an essential role in confronting the global climate challenge. Nuclear facilities are not only emissions free, but they are also the most reliable assets in the power generation mix, operating under circumstances often requiring fossil fuel and renewable energy plants to cease or curtail their operations, such as extreme weather conditions.

As the country’s leading uranium and vanadium producer, Energy Fuels is well positioned to capitalize on the growing demand for clean energy. Energy Fuels has also recycled over 6 million pounds of uranium from its alternate feed recycling program. The carbon-free electricity produced from this recycled uranium would be the equivalent of a train full of coal that stretched from Los Angeles to New York — and back again — thereby avoiding 85 million tons of CO2 emissions.  Among clean-energy options, nuclear is recognized as one of the most reliable, affordable and stable, contributing to 55% of all clean-energy production throughout the country in 2019 (http://nnw.fm/fvRMJ). In terms of carbon emissions and air pollution reduction, Energy Fuels is one of the greenest companies operating in the U.S.

As the push for clean energy gains momentum, the global market shows signs of imbalance with global demand for uranium ore concentrate estimated to exceed production by 1 billion pounds over 2019–2040. Reflecting an international surge in nuclear power activity, global uranium prices have been improving globally with a 34% increase since March 2020 amid significant production cuts due to COVID-19 (http://nnw.fm/0rKIj). The global boost for nuclear energy, combined with the declared U.S. national policy to revitalize the nuclear sector and preserve domestic infrastructure to regain U.S. global nuclear leadership, distinguishes Energy Fuels, the country’s top producer of uranium, as a clear leader in the space.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Many clinical researchers are still doing their work behind closed doors. Despite being in the middle of the pandemic, they have tried to keep their trials or tests going remotely and they would want to open again fully. It is not the researchers alone who are eager for the research sites to open. Other stakeholders, including interns, have found themselves in that dilemma.

For instance, in the U.S., the three-phase plan for reopening the country indicates that researchers may return to work soon. As your research teams are preparing to return to their work stations, the safety of patients and staff must be a top priority. Clear policies for how your staff will be conducting their research activities once they are safe to return are needed. The following safety measures can allow the safe reopening of research sites:

Recommendations from the Centers for Disease Control and Prevention

Safe distancing in the workplace is one of the safety policies that have to be in place in the working areas. It will reduce contact between people at their work stations, hence making them safe. Safe distancing will be possible by doing the following:

• Employees should be working in shifts, thus limiting the number of people within the working site.
• The number of people congregating at the conference and break rooms should also reduce.

Changing the Design of the Sites to Allow for Safe Distancing During Monitoring Hours

Your research site should have a new design to minimize close contact during monitoring hours. For instance, you may consider doing the following:

• Setting up private working areas or conference rooms for monitor(s) away from your patients and staff.
• Resolving queries through web meetings and telephones even if you are close with the monitor.
• Wearing of masks by monitors when visiting the site.

Complete Your Site Initiation Visits

It would be best if you strived to think about how the study start-up activities will continue to progress. It will enable your sponsors to come in and help you finish the following activities quickly.

• Obtain the study documents and work with your staff to complete the forms.
• Conducting all pieces of training remotely (e.g., EDC, protocol, eTMF)

Ensuring Patients are Safe During Study Visits

Proper sanitation should always be in place within your site, and washing of hands with soap and water should be a norm within site. Some of these other protocols should also be in place:

• Rearranging of patients’ waiting rooms and common areas to ensure safe distancing
• Limit face-to-face contact by conducting follow up visits remotely

Changing the Schedule of Your Business

This is an era of “new normal”; hence things will be conducted differently. It would be best if you considered whether the research activities would be taking place remotely or onsite. The following should be considered:

• Can you gain access to the institution’s Electronic Medical Records and how challenging is the process?
• Are source documents accessible, and can they be securely shared through ShareFile or Box?

By following the measures mentioned above, the reopening of research sites will be possible, and the research will also be conducted efficiently. It would be interesting to hear what companies like Predictive Oncology (NASDAQ: POAI) are doing to resume full operations after the worst of the pandemic is behind us.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

As 2018 drew to a close, Congress passed the 2018 Farm Bill, legislation that finally ended the federal prohibition of industrial hemp and all of its cannabinoids. Just a few months into 2019, there was already a booming market for cannabidiol (“CBD”), one of the over 100 chemicals produced by hemp. Initial research had found the cannabinoid effective against a variety of medical conditions and soon after it was legalized, there was a plethora of CBD products on the shelves.

As it is still new and barely regulated, the industry represents a minefield for first-time buyers who don’t know their way around. Although there are lots of good, honest firms selling CBD, there are plenty of bad players as well. So how does a customer get their money’s worth when they purchase CBD?

Buy high-quality CBD products. A sizeable percentage of the CBD products on the market are either contaminated or don’t contain nearly enough CBD. Plenty of sellers are willing to cut corners, quality-wise, and the end product isn’t as effective as it should be. High-quality contaminant free product will have enough CBD for the treatment to be effective.

Follow the instructions. CBD affects everyone in different ways. The cannabinoid interacts with a part of the nervous system called the endocannabinoid system, and how the CBD affects you depends on a variety of factors like age and gender. However, trustworthy sellers include instructions on the packaging, and each brand and product contains different dosages and might be consumed in different ways. Follow the instructions and you will steadily find out the dosage that works for you.

Keep a schedule. Cannabidiol has a long term effect when it’s used consistently. Once you’ve figured out the dosage and frequency that is most effective for you, use the CBD product consistently and preferably at the same time every day. As you do this, the CBD will steadily build up in your system and over time, smaller doses of the cannabinoid will produce stronger effects. So don’t call it quits after the first couple of days, even if it produces positive results.

Don’t forget about the other cannabinoids. THC, or delta-9 tetrahydrocannabinol, is the chemical responsible for cannabis’ infamous high. Alongside CBD, it’s one of the over 100 cannabinoids produced by the cannabis plant. When CBD is consumed in unison with other cannabinoids, it results in stronger benefits, something called the entourage effect. The chemicals work in unison and this amplifies their benefits. Full-spectrum CBD products contain CBD, other chemicals as well as terpenes.

Invest in high-quality CBD, preferably full-spectrum CBD products to take advantage of the entourage effect. Follow the instructions provided and take the cannabinoid consistently for significant positive results. If in doubt, companies like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) are always willing to answer any questions you may have.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

• The need for efficient drug procurement and delivery has never been more in demand
• Trxade Group’s unmatched supply chain trading platform represents a unique portal to speeding up drug distribution
• Such efficiencies are key to improving margins and keeping America’s independent pharmacies alive

Not in recent memory have medical services and associated support personnel been viewed as more vital to the nation. Just as indispensable, but not as visible, are the supply chain channels through which medical supplies flow, for doctors without medicines may be so handicapped as to be useless. So too would be pharmacies where the bulk of medicines are dispensed. As a result, it is crucial that these supply chain channels operate efficiently.

One company has been working specifically toward that end. Trxade Group (NASDAQ: MEDS) has developed an integrated drug procurement and delivery platform that is improving supply chain and market efficiency, speeding up distribution of drugs while also ensuring critical transparency on prices. This is good news for independent pharmacies; direct dealing on the platform will lead to improved margins. And consumers will undoubtedly welcome the platform’s price discovery capabilities. The Trxade digital pharmaceutical exchange is set to shakeup the staid drug distribution business.

Trxade’s web-based platform has something for everyone. Patients will benefit from the lower prices its algorithms identify, while pharmacies are now more likely to avoid negative reimbursement costs, which flatten profit margins. Close to half the number of independent pharmacies operating across the nation are registered users on the Trxade platform. The company expects 2019’s signup rate—8 or 9 new pharmacies every day—to continue throughout 2020. There is good reason for those expectations. For a long time, America’s independent pharmacies haven’t been getting a good deal.

The U.S. pharmaceutical industry is a sprawling system made up of around 65,000 pharmacies. Most are branches of the large chains. A recent report provides a snapshot of the landscape (http://nnw.fm/5F8lR). CVS Pharmacy, the largest, employs 18,631 pharmacists in close to 9,105 stores. Walgreens has 17,437 pharmacists working in its 7,713 or so stores, while Rite Aid with its 4,515 stores employs 9,194 pharmacists. Walmart has less stores (4,403) than Rite Aid but employs more pharmacists (10,458). This colossal operation moves around $330 billion worth of pharmaceuticals per annum. But most of the business goes to the giant chains with their thousands of retail outlets and their ability to capture significant excess margin at the cost of the consumer, employers and government.

This leaves about one-third of the nation’s pharmacies that are run independently, that do not belong to a large corporate chain. These smaller independent pharmacies tend, on average, to be $3.5 million-per-annum enterprises owned and managed, typically, owner operated vocational pharmacists. Predictably, they struggle to stay afloat, surviving on thin margins that continuously pose an existential threat.

The presence of pharmacy benefit managers (“PBMs”) hasn’t really helped. These third party administrators of prescription drug programs were expected to reduce the purchase costs of drugs across the board and they have but the benefits have accrued to a select few. The three largest PBMs— Caremark (CVS Health) / Aetna, Express Scripts, OptumRx (UnitedHealth)—now control 76 percent of the market. And, as the Brookings Institution has pointed out in testimony to Congress, “health care markets are becoming more consolidated, causing price increases for purchasers of health services…” (http://nnw.fm/L35ua).

However, Trxade’s pharmaceutical platform gives independent pharmacies a real shot at reducing their purchasing costs, and much more. The integrated pharmaceutical services company offers not just a web-based purchasing platform for transactions between independent pharmacists and drug distributors (“B2B”), but a network of associated pharmacies with its E-Hub software, and a mail order pharmacy, as well as warehouse and drug delivery services.

Called the Trxade Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution network, allowing them to search for and view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. Trxade is hoping that the majority of America’s 24,000 independent pharmacies, who which together have a combined annual purchasing power of over $92 billion, will eventually see how Trxade’s supportive platform that can make their businesses more profitable.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.